This was the stock's second consecutive day of losses.

Matt Miksic from Barclays lowered the price target on Becton, Dickinson, and Company (NYSE:BDX) from $261 to $241, while ...

HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.

The stock's rise snapped a four-day losing streak.

Fintel reports that on May 22, 2025, Citigroup downgraded their outlook for Becton, Dickinson and (NYSE:BDX) from Buy to ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

6 analysts have shared their evaluations of Becton Dickinson BDX during the recent three months, expressing a mix of bullish ...

Discover six Dividend Kings offering fair value with high dividend yields. Explore top picks like Altria and Northwest ...

The global single-cell analysis Market is expected to witness a growth rate of 14% in the next five years. Continuous ...

BD is set to commence a multi-centre registry study, XTRACT, of the Rotarex Atherectomy System, for peripheral artery disease ...

Generation Investment Management's Q1 2025 13F portfolio value dropped to $16.56B. Check out the significant stake increases ...